Intellia Therapeutics Announces Proposed Public Offering of Common Stock
30 Novembre 2022 - 10:36PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing potentially curative
therapies leveraging CRISPR-based technologies, today announced
that it has commenced an underwritten public offering of $250
million of shares of its common stock. Intellia also intends to
grant the underwriters a 30-day option to purchase up to an
additional fifteen percent (15%) of the shares of common stock
offered in the public offering. All of the shares in the proposed
offering are to be sold by Intellia.
Goldman Sachs & Co. LLC is acting as the sole underwriter
for the proposed offering. The offering is subject to market and
other conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
The shares of common stock are being offered by Intellia
pursuant to an effective shelf registration statement that was
previously filed with the U.S. Securities and Exchange Commission
(SEC). A preliminary prospectus supplement and accompanying
prospectus relating to and describing the terms of the offering
will be filed with the SEC and may be obtained, when available,
from: Goldman Sachs & Co. LLC, by mail at 200 West Street, New
York, NY 10282, Attention: Prospectus Department, by telephone at
(866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or by
accessing the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing
company, is developing novel, potentially curative therapeutics
leveraging CRISPR-based technologies. To fully realize the
transformative potential of CRISPR-based technologies, Intellia is
pursuing two primary approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the therapy by
using engineered human cells to treat cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its robust intellectual property
portfolio, have enabled the company to take a leadership role in
harnessing the full potential of genome editing to create new
classes of genetic medicine. Learn more at intelliatx.com. Follow
us on Twitter @intelliatx.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Intellia’s anticipated public offering. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, such as the
intended offering terms, are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, uncertainties related to market
conditions and the completion of the public offering on the
anticipated terms or at all. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in Intellia’s most recent annual report on
Form 10-K and quarterly report on Form 10-Q filed with the SEC, as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with the SEC,
including those contained or incorporated by reference in the
preliminary prospectus supplement and accompanying prospectus
related to the proposed public offering to be filed with the SEC.
Any forward-looking statements contained in this press release
represent Intellia’s views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date. Intellia explicitly disclaims any obligation to update any
forward-looking statements, except as required by law.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiSenior Director, Investor Relations and Corporate
Communications+1-857-706-1612lina.li@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024